Technical Specifications
PROVA-SEAL – PBS10FLOZCDN - WHITE EFFECTIVE DATE: MARCH 3, 2015
PAGE 5 OF 10
11. TOXICOLOGICAL INFORMATION (Continued)
TOXICITY DATA: Currently, the following toxicological data are available for
some components of 1% or more concentration.
ACRYLIC POLYMERS:
LD
50
(Oral-Rat) > 5000 mg/kg
LD
50
(Skin-Rabbit) > 5000 mg/kg
CALCIUM CARBONATE:
TDLo (Intravenous-Rat) 30 mg/kg: Vascular: BP lowering not characterized in
autonomic section; Lungs, Thorax, or Respiration: changes in lung weight; Blood:
other changes
TCLo (Inhalation-Rat) 84 mg/m
3
/4 hours/40 weeks-intermittent: Lungs, Thorax, or
Respiration: fibrosis (interstitial); Liver: other changes; Kidney/Ureter/Bladder: other
changes
TCLo (Inhalation-Rat) 250 mg/m
3
/2 hours/24 weeks-intermittent: Lungs, Thorax, or
Respiration: fibrosis, focal (pneumoconiosis)
DIISONONYL PHTHALATE:
IC
50
(In vitro-Human-melanoma) > 1000 mg/L/48 hours: In Vitro Toxicity Studies: cell
viability (lysosomal damage): neutral red assay etc.
LD
50
(Oral-Rat) >10,000 mg/kg: Lungs, Thorax, or Respiration: respiratory depression
LD
50
(Skin-Rabbit) > 3160 mg/kg
LC
50
(Inhalation-Rat) > 67 mg/m
3
/6 hours
LC
50
(Inhalation-Mouse) > 67 mg/m
3
/6 hours
LC
50
(Inhalation-Guinea Pig) > 67 mg/m
3
/6 hours
TDLo (Oral-Rat) 10,080 mg/kg/2 weeks-continuous: Liver: other changes
TDLo (Oral-Rat) 85,880 mg/kg/113 days-continuous: Liver: changes in liver weight;
Kidney/Ureter/Bladder: changes in kidney weight; Related to Chronic Data: changes
in ovarian weight
TDLo (Oral-Rat) 45,765 mg/kg/113 days-continuous: Nutritional and Gross Metabolic:
weight loss or decreased weight gain
TDLo (Oral-Rat) 11,413 mg/kg/113 days-continuous: Liver: changes in liver weight
TDLo (Oral-Rat) 44,800 mg/kg/70 days-continuous: Nutritional and Gross Metabolic:
weight loss or decreased weight gain
TDLo (Oral-Rat) 22,400 mg/kg/70 days-continuous: Liver: changes in liver weight;
Kidney/Ureter/Bladder: changes in kidney weight
TDLo (Oral-Rat) 67,200 mg/kg/70 days-continuous: Related to Chronic Data: changes
in testicular weight
TDLo (Oral-Rat) 16,450 mg/kg/70 days-continuous: Kidney/Ureter/Bladder: changes in
kidney weight
TDLo (Oral-Rat) 32,900 mg/kg/70 days-continuous: Liver: changes in liver weight
TDLo (Oral-Rat) 45,000 mg/kg/90 days-continuous: Liver: changes in liver weight;
Kidney/Ureter/Bladder: changes in kidney weight
TDLo (Oral-Rat) 20,657 mg/kg/13 weeks-continuous: Liver: changes in liver weight;
Kidney/Ureter/Bladder: changes in kidney weight
TDLo (Oral-Rat) 12,600 mg/kg/21 days-continuous: Liver: changes in liver weight;
Blood: changes in serum composition (e.g. TP, bilirubin, cholesterol); Biochemical:
Enzyme inhibition, induction, or change in blood or tissue levels: multiple enzyme
effects
TDLo (Oral-Rat) 1133 gm/kg/4 years-continuous: Tumorigenic: equivocal tumorigenic
agent by RTECS criteria; Kidney/Ureter/Bladder: Kidney tumors
TDLo (Oral-Rat) 405 gm/kg/79 weeks-continuous: Tumorigenic: equivocal tumorigenic
agent by RTECS criteria; Liver: tumors
TDLo (Oral-Rat) 10 gm/kg: female 6-15 day(s) after conception: Reproductive: Effects
on Embryo or Fetus: fetotoxicity (except death, e.g., stunted fetus)
TDLo (Oral-Rat) 153 gm/kg: male 70 day(s) pre-mating female 70 day(s) pre-mating: 3
week(s) post-birth: Reproductive: Effects on Newborn: live birth index (measured
after birth), weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TDLo (Oral-Rat) 510 gm/kg: male 70 day(s) pre-mating female 70 day(s) pre-mating: 3
week(s) post-birth: Reproductive: Effects on Newborn: growth statistics (e.g.%,
reduced weight gain)
TDLo (Oral-Rat) 20 gm/kg: male 70 day(s) pre-mating female 70 day(s) pre-mating: 21
day(s) post-birth: Reproductive: Fertility: litter size (e.g. # fetuses per litter; measured
before birth); Specific Developmental Abnormalities: hepatobiliary system; Effects on
Newborn: growth statistics (e.g.%, reduced weight gain)
TDLo (Oral-Rat) 79 gm/kg: male 70 day(s) pre-mating female 70 day(s) pre-mating: 21
day(s) post-birth: Reproductive: Specific Developmental Abnormalities: hepatobiliary
system, urogenital system
TDLo (Oral-Rat) 109 mg/kg: Multi-Generations: Reproductive: Fertility: litter size (e.g. #
fetuses per litter; measured before birth); Specific Developmental Abnormalities:
hepatobiliary system
TDLo (Oral-Rat) 219 mg/kg: Multi-Generations: Reproductive: Effects on Newborn:
growth statistics (e.g.%, reduced weight gain)
TDLo (Oral-Rat) 39 gm/kg: male 70 day(s) pre-mating female 70 day(s) pre-mating: 21
day(s) post-birth: Reproductive: Specific Developmental Abnormalities: urogenital
system
TDLo (Oral-Rat) 1000 mg/kg: female 6-15 day(s) after conception: Reproductive:
Specific Developmental Abnormalities: urogenital system
TDLo (Oral-Rat) 5000 mg/kg: female 6-15 day(s) after conception: Reproductive:
Specific Developmental Abnormalities: musculoskeletal system
TDLo (Oral-Rat) 10 gm/kg: female 6-15 day(s) after conception: Reproductive: Fertility:
post-implantation mortality (e.g. dead and/or resorbed implants per total number of
implants); Specific Developmental Abnormalities: musculoskeletal system, urogenital
system
TDLo (Oral-Rat) 33 gm/kg: male 10 week(s) pre-mating female 10 week(s) pre-mating:
3 week(s) post-birth: Reproductive: Effects on Newborn: growth statistics (e.g.%,
reduced weight gain)
TDLo (Oral-Rat) 16,500 mg/kg: female 14 day(s) after conception: 3 day(s) post-birth:
Reproductive: Specific Developmental Abnormalities: urogenital system
TDLo (Oral-Rat) 10,000 mg/kg: female 6-15 day(s) after conception: Reproductive:
Maternal Effects: other effects; Effects on Embryo or Fetus: fetotoxicity (except
death, e.g., stunted fetus)
TDLo (Oral-Mouse) 6720 mg/kg/1 week-intermittent: Liver: changes in liver weight;
Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: other
oxidoreductases; Biochemical: Metabolism (Intermediary): lipids including transport
DIISONONYL PHTHALATE (continued):
TDLo (Oral-Mouse) 10,080 mg/kg/2 weeks-continuous: Liver: other changes, changes
in liver weight
TDLo (Oral-Mouse) 2520 mg/kg/2 weeks-intermittent: Liver: changes in liver weight
TDLo (Oral-Mouse) 1086 gm/kg/4 years-continuous: Tumorigenic: equivocal
tumorigenic agent by RTECS criteria; Liver: tumors
TDLo (Oral-Mouse) 2764 gm/kg/4 years-continuous: Tumorigenic: equivocal
tumorigenic agent by RTECS criteria; Liver: tumors
TDLo (Oral-Mouse) 65700 mg/kg/2 years-intermittent: Tumorigenic: neoplastic by
RTECS criteria, increased incidence of tumors in susceptible strains; Liver: tumors
TDLo (Oral-Dog) 182,000 mg/kg/13 weeks-continuous: Liver: other changes, changes
in liver weight; Biochemical: Enzyme inhibition, induction, or change in blood or
tissue levels: multiple enzyme effects
TDLo (Oral-Monkey) 7 gm/kg/14 days-intermittent: Blood: changes in other cell count
(unspecified)
TDLo (Oral-Monkey) 227,500 mg/kg/13 weeks-continuous: Nutritional and Gross
Metabolic: weight loss or decreased weight gain
TDLo (Unreported-Rat) 41,250 mg/kg: female 14 day(s) after conception: 3 day(s) post-
birth: Reproductive: Specific Developmental Abnormalities: urogenital system
PROPYLENE GLYCOL:
Standard Draize Test (Skin-Human) 500 mg/7 days: Mild
Standard Draize Test (Skin-Human) 104 mg/3 days-intermittent: Moderate
Standard Draize Test (Skin-Man) 10%/2 days
Standard Draize Test (Skin-Child) 30%/96 hours-continuous: Moderate
Open Irritation Test (Skin-woman) 30%/96 hours: Mild
TDLo (Oral-Child) 79 gm/kg/56 weeks-intermittent: Brain and Coverings: changes in
surface EEG; Behavioral: general anesthetic, convulsions or effect on seizure
threshold
TDLo (Skin-Human) 10 pph: Skin and Appendages: dermatitis, allergic (after topical
exposure)
TDLo (Parenteral-Infant) 10 gm/kg/3 days-continuous: Nutritional and Gross Metabolic:
other changes
TDLo (Skin-Human) 5 mg/kg/7 days-intermittent: Skin and Appendages: primary
irritation (after topical exposure)
TDLo (Skin-Human) 4.5 mg/kg/3 days-intermittent: Skin and Appendages: primary
irritation (after topical exposure)
TDLo (Skin-Human) 10 pph/48 hours-continuous: Skin and Appendages: dermatitis,
allergic (after topical exposure)
TDLo (Skin-Man) 0.03 mL/kg/22 days-intermittent: Skin and Appendages: cutaneous
sensitization, experimental (after topical exposure)
TDLo (Intravenous-Woman) 5167 mg/kg/13 days-continuous: Nutritional and Gross
Metabolic: metabolic acidosis
Standard Draize Test (Eye-Rabbit) 100 mg: Mild
Standard Draize Test (Eye-Rabbit) 500 mg/24 hours: Mild
LD
50
(Oral-Rat) 20 gm/kg
LD
50
(Oral-Mouse) 22 gm/kg
LD
50
(Oral-Mouse) 20,300 mg/kg: Behavioral: ataxia, tetany; Lungs, Thorax, or
Respiration: respiratory depression
LD
50
(Oral-Rabbit) 18,500 mg/kg
LD
50
(Oral-Dog) 22 gm/kg
LD
50
(Oral-Dog) 22,000 mg/kg: Behavioral: ataxia, tetany; Lungs, Thorax, or
Respiration: respiratory depression
LD
50
(Oral-Guinea Pig) 18,350 mg/kg
LD
50
(Oral-Guinea Pig) 19,000 mg/kg: Behavioral: ataxia, tetany Lungs, Thorax, or
Respiration: respiratory depression
HEALTH HAZARD
FLAMMABILITY HAZARD
PHYSICAL HAZARD
PROTECTIVE EQUIPMENT
1*
EYES
RESPIRATORY
HANDS
BODY
(BLUE)
(RED)
For Routine Industrial Use and Handling Applications
SEE SECTION 8
HAZARDOUS MATERIAL IDENTIFICATION SYSTEM
(YELLOW)
1
0
SEE SECTION 8
Hazard Scale: 0 = Minimal 1 = Slight 2 = Moderate
3 = Serious 4 = Severe * = Chronic hazard